Weight-loss medications can shrink the hazard of deteriorateing kidney function, kidney fall shorture and dying from kidney disrelieve by a fifth, according to a study.
Glucagon-enjoy peptide-1 (GLP-1) receptor agonists are a family of medications that help people shed the pounds, deal with blood sugar in accomprehendledgeings with type 2 diabetes and impede heart strikes and strokes in people with heart disrelieve.
But while the profits of the medications for treating obesity, type 2 diabetes and cardiovascular disrelieve are well comprehendn, their potential impact on kidney health has been less confident.
Now the hugest and most comprehensive analysis of GLP-1 receptor agonists on kidney outcomes recommends they could have meaningful profits. The findings were rehireed in the Lancet Diabetes & Endocrinology journal.
Researchers directed a meta-analysis of 11 huge-scale clinical trials of weight loss medications involving more than 85,000 people. The group comprised people with type 2 diabetes, and people with cardiovascular disrelieve who were overweight or overweight but did not have type 2 diabetes.
Seven contrastent GLP-1 receptor agonists were scatterigated among the trials, including semaglutide, also comprehendn as Ozempic or Wegovy, dulaglutide and liraglutide.
Compared with placebo, GLP-1 receptor agonists shrinkd the hazard of kidney fall shorture by 16% and the deteriorateing of kidney function by 22%, researchers shelp. The combined reduction in the hazard of kidney fall shorture, deteriorateing kidney function and death due to kidney disrelieve was 19%.
The analysis also examineed previous findings that weight-loss medications protect cardiovascular health, with a 14% reduction in the hazard of cardiovascular death, non-overweightal heart strike and non-overweightal stroke, contrastd with placebo. Death by any cause was 13% shrink among accomprehendledgeings treated with GLP-1 receptor agonists.
Lead author Prof Sunil Badve, professorial fellow at the George Institute for Global Health and UNSW Sydney, shelp the study broadened current comprehendledge about the potential profits of the medications.
“This is the first study to show a evident profit of GLP-1 receptor agonists on kidney fall shorture or finish-stage kidney disrelieve, recommending they have a key role in kidney-protective and heart-protective treatment for accomprehendledgeings with common medical conditions enjoy type 2 diabetes, overweight or obesity with cardiovascular disrelieve, or CKD [chronic kidney disease],” he shelp.
“These results are particularly meaningful for accomprehendledgeings with chronic kidney disrelieve. It is a enhanceive condition eventuassociate directing to kidney fall shorture requiring dialysis or kidney transset uptation and is associated with preenlargen-up death, mostly from heart disrelieve. It has a meaningful impact on accomprehendledgeings’ quality of life and incurs substantial healthattfinish costs.”
CKD is appraised to impact one in 10 people worldexpansive, equivalent to about 850 million people. It is the 10th directing cause of death and is projected to become the fifth most common cause of death by 2050.
Prof Vlado Perkovic, professorial fellow at the George Institute, provost at UNSW Sydney and better author on the study, shelp: “This research shows that GLP-1 receptor agonists could percreate an meaningful role in compriseressing the global burden of non-communicable disrelieves.
“Our study will have a presentant impact on clinical directlines for the deal withment of chronic kidney disrelieve and cardiovascular disrelieve in people with and without diabetes.
“More toil is now necessitateed to carry out the results of this study into clinical train and better access to GLP-1 receptor agonists to people who will profit from them.”
